Hepatic venous outflow tract obstruction: treatment ou prognostic score

Alimentary Pharmacology and Therapeutics 43, 1154-1167

DOI: 10.1111/apt.13604

Citation Report

#	Article	IF	CITATIONS
1	Editorial: shortâ€kength stenoses of hepatic venous outflow tract – an Asian specificity? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 201-202.	3.7	0
2	Editorial: shortâ€length stenoses of hepatic venous outflow tract – an Asian specificity?. Alimentary Pharmacology and Therapeutics, 2016, 44, 200-201.	3.7	1
3	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 538-580.	0.1	10
4	Enfermedades vasculares del hÃgado. GuÃas ClÃnicas de la Sociedad Catalana de DigestologÃa y de la Asociación Española para el Estudio del HÃgado. GastroenterologÃa Y HepatologÃa, 2017, 40, 538-580.	0.5	20
5	Long-term outcomes of transjugular intrahepatic portosystemic shunt in Indian patients with Budd–Chiari syndrome. European Journal of Gastroenterology and Hepatology, 2017, 29, 1174-1182.	1.6	23
6	Budd-Chiari Syndrome and Inferior Vena Cava Obstruction: The Asian Perspective., 2018,, 257-269.		O
7	Budd-Chiari Syndrome: The Western Perspective. , 2018, , 241-255.		0
8	Budd–Chiari syndrome/hepatic venous outflow tract obstruction. Hepatology International, 2018, 12, 168-180.	4.2	93
9	Image-guided treatment of Budd-Chiari syndrome: a giant leap from the past, a small step towards the future. Abdominal Radiology, 2018, 43, 1908-1919.	2.1	6
10	Outcomes of endovascular interventional therapy for primary Budd‑Chiari syndrome caused by hepatic venous obstruction. Experimental and Therapeutic Medicine, 2018, 16, 4141-4149.	1.8	6
11	Timing of transjugular intrahepatic portosystemic stent-shunt in Budd–Chiari syndrome: A UK hepatologist's perspective. Journal of Translational Internal Medicine, 2018, 6, 97-104.	2.5	9
12	Review article: a multidisciplinary approach to the diagnosis and management of Buddâ€Chiari syndrome. Alimentary Pharmacology and Therapeutics, 2019, 49, 840-863.	3.7	33
13	Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome postâ€percutaneous endovascular intervention. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 654-662.	2.8	29
14	Acute-on-Chronic Liver Failure in Budd–Chiari Syndrome: Profile and Predictors of Outcome. Digestive Diseases and Sciences, 2020, 65, 2719-2729.	2.3	14
15	Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis. Journal of Clinical and Experimental Hepatology, 2020, 10, 339-376.	0.9	38
16	Behcet's Disease With Budd-Chiari Syndrome and Challenges in Its Management. ACG Case Reports Journal, 2020, 7, e00352.	0.4	2
17	Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant. Current Hepatology Reports, 2020, 19, 197-202.	0.9	1
18	An Update on the Management of Budd–Chiari Syndrome. Digestive Diseases and Sciences, 2021, 66, 1780-1790.	2.3	33

#	Article	IF	CITATIONS
19	Long-Term Outcomes of Endovascular Interventions in More than 500 patients with Budd–Chiari Syndrome. Journal of Vascular and Interventional Radiology, 2021, 32, 61-69.e1.	0.5	13
20	Management of portal hypertension severe complications. Minerva Gastroenterology, 2021, 67, .	0.5	3
21	Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). Hepatology International, 2021, 15, 531-567.	4.2	41
22	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, 1636-1662.e36.	4.4	95
23	Hepatic Venous Outflow Tract Obstruction: Causes, Natural History, and Treatment. Clinical Liver Disease, 2021, 18, 117-121.	2.1	2
24	Prognostic Assessment of Budd–Chiari Syndrome. , 2020, , 189-205.		0
25	Budd–Chiari Syndrome: East versus West. , 2020, , 231-243.		2
26	Budd Chiari Syndrome and Intrahepatic Cholangiocarcinoma, An Unusual Combination: Case Report and Review of the Literature. , 2020, 24, 1-3.		2
27	Clinical Utility of Transient Elastography in the Management of Patients with Budd-Chiari Syndrome undergoing Endovascular Intervention. Journal of Vascular and Interventional Radiology, 2021, , .	0.5	3
28	Reply to "Re: Clinical utility of transient elastography in the management of patients with Budd-Chiari syndrome undergoing endovascular intervention.― Journal of Vascular and Interventional Radiology, 2022, , .	0.5	1
29	State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review. Journal of Clinical Medicine Research, 2022, 14, 147-157.	1.2	6
30	Vascular Disorders. , 2022, , 405-436.		0
31	Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes. Scientific Reports, 2022, 12, .	3.3	0
33	Treatment Options for Hepatic Venous Outflow Tract Obstruction: Is the Scale Tipping in Favor of TIPS?. Journal of Clinical and Experimental Hepatology, 2022, , .	0.9	0
34	Establishment and validation of a prediction model for the first recurrence of Budd–Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study. Hepatology International, 2023, 17, 159-169.	4.2	0
35	Pregnancy outcomes in patients with Budd–Chiari syndrome: A tertiary care experience. Indian Journal of Gastroenterology, 2023, 42, 96-105.	1.4	3
36	Outflow obstruction after living donor liver transplantation managed with a temporary vena cava filter: A case report. International Journal of Surgery Case Reports, 2023, 112, 108981.	0.6	0
37	Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome. World Journal of Gastrointestinal Oncology, 0, 16, 699-715.	2.0	0